Pyxis Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Pyxis Oncology
PYXS Stock  USD 1.07  0.01  0.94%   
Pyxis Oncology financial statements provide useful quarterly and yearly information to potential Pyxis Oncology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pyxis Oncology financial statements helps investors assess Pyxis Oncology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pyxis Oncology's valuation are summarized below:
Gross Profit
15.7 M
Market Capitalization
63 M
Enterprise Value Revenue
5.0821
Revenue
16.1 M
Earnings Share
(1.06)
There are over one hundred nineteen available trending fundamental ratios for Pyxis Oncology, which can be analyzed over time and compared to other ratios. All traders should check out Pyxis Oncology's recent fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 86.6 M in 2025. Enterprise Value is likely to drop to about 87.3 M in 2025
Check Pyxis Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pyxis Oncology's main balance sheet or income statement drivers, such as Net Interest Income of 8.3 M, Interest Income of 8.3 M or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 4.52, Dividend Yield of 0.0 or PTB Ratio of 0.79. Pyxis financial statements analysis is a perfect complement when working with Pyxis Oncology Valuation or Volatility modules.
  
Check out the analysis of Pyxis Oncology Correlation against competitors.
For more information on how to buy Pyxis Stock please use our How to Invest in Pyxis Oncology guide.

Pyxis Oncology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets156.2 M157.2 M74.2 M
Slightly volatile
Short and Long Term Debt Total11.3 M20.2 M4.6 M
Slightly volatile
Other Current Liabilities10.5 M11.4 M4.2 M
Slightly volatile
Total Current Liabilities18 M17.7 M7.7 M
Slightly volatile
Property Plant And Equipment Net13.7 M22.1 M5.6 M
Slightly volatile
Current Deferred Revenue4.4 M8.8 M2.4 M
Slightly volatile
Accounts Payable5.4 M4.9 M2.4 M
Slightly volatile
Cash18.5 M19.5 M44.2 M
Slightly volatile
Non Current Assets Total18.7 M24.7 M7.6 M
Slightly volatile
Non Currrent Assets Other16.4 M15.6 M3.7 M
Slightly volatile
Cash And Short Term Investments133.5 M126.9 M64.9 M
Slightly volatile
Common Stock Shares Outstanding42.6 M58.4 M36.5 M
Slightly volatile
Liabilities And Stockholders Equity156.2 M157.2 M74.2 M
Slightly volatile
Non Current Liabilities Total15.5 M18.8 M20.6 M
Slightly volatile
Capital Lease Obligations25.8 M24.5 M5.7 M
Slightly volatile
Other Current Assets3.9 M5.5 M1.6 M
Slightly volatile
Other Stockholder Equity254.1 M484.1 M102.5 M
Slightly volatile
Total Liabilities37.1 M36.4 M27.7 M
Slightly volatile
Property Plant And Equipment Gross34.3 M32.7 M7.8 M
Slightly volatile
Total Current Assets137.5 M132.4 M66.6 M
Slightly volatile
Capital Stock54.3 K51.8 K14.3 K
Slightly volatile
Net Working Capital118.2 M113.7 M58.7 M
Slightly volatile
Short Term Debt799.9 K1.4 M359.3 K
Slightly volatile
Common Stock31.7 K60 K13.4 K
Slightly volatile
Property Plant Equipment13.5 M12.8 M3.3 M
Slightly volatile
Common Stock Total Equity36.3 K39.1 K33 K
Slightly volatile
Capital Surpluse399.4 M429.2 M363.2 M
Slightly volatile
Net Receivables18 K18.9 K489.5 K
Slightly volatile
Inventory699.2 K786.6 K857.6 K
Slightly volatile
Non Current Liabilities Other15.1 M17 M18.6 M
Slightly volatile
Intangible Assets2.5 M2.6 M21.6 M
Slightly volatile

Pyxis Oncology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income8.3 M7.9 M1.7 M
Slightly volatile
Interest Income8.3 M7.9 M1.7 M
Slightly volatile
Depreciation And Amortization2.4 M2.3 M636.8 K
Slightly volatile
Selling General Administrative21.9 M25.4 M9.8 M
Slightly volatile
Other Operating Expenses72.7 M105.6 M31 M
Slightly volatile
Research Development46.6 M58.7 M19.5 M
Slightly volatile
Total Operating Expenses72.7 M105.1 M30.9 M
Slightly volatile
Cost Of Revenue451.2 K475 K681.1 K
Slightly volatile
Selling And Marketing Expenses1.4 M1.6 M1.7 M
Slightly volatile

Pyxis Oncology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9.6 M12.9 M3.9 M
Slightly volatile
Begin Period Cash Flow10.6 M11.1 M31.7 M
Slightly volatile
Depreciation3.1 M3 M909.7 K
Slightly volatile
Capital Expenditures225.2 K237 K1.9 M
Pretty Stable
Change To Operating Activities1.5 M2.3 M859.6 K
Slightly volatile
Issuance Of Capital Stock6.7 M7 M43.5 M
Pretty Stable
Total Cash From Financing Activities52.2 M59.3 M40.1 M
Pretty Stable
End Period Cash Flow19.9 M20.9 M44.7 M
Slightly volatile
Change To Liabilities3.9 M4.2 M1.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.525.085.5411
Slightly volatile
Stock Based Compensation To Revenue0.640.720.7865
Slightly volatile
Capex To Depreciation0.07550.07953.018
Pretty Stable
EV To Sales4.555.125.5848
Slightly volatile
Inventory Turnover1.681.892.0612
Slightly volatile
Days Of Inventory On Hand139156170
Slightly volatile
Payables Turnover0.09290.09780.3501
Slightly volatile
Sales General And Administrative To Revenue1.261.421.5451
Slightly volatile
Research And Ddevelopement To Revenue2.913.273.5699
Slightly volatile
Capex To Revenue0.01180.01320.0144
Slightly volatile
Cash Per Share2.662.17181.7344
Slightly volatile
Days Payables Outstanding3.9 K3.7 K1.4 K
Slightly volatile
Income Quality0.60.74580.7733
Slightly volatile
Intangibles To Total Assets0.01570.01650.1244
Slightly volatile
Current Ratio11.417.49119.7189
Slightly volatile
Capex Per Share0.00390.00410.0539
Pretty Stable
Revenue Per Share0.220.250.2711
Slightly volatile
Interest Debt Per Share0.20.34560.1053
Slightly volatile
Debt To Assets0.130.12850.0347
Slightly volatile
Operating Cycle139156170
Slightly volatile
Days Of Payables Outstanding3.9 K3.7 K1.4 K
Slightly volatile
Ebt Per Ebit1.070.88860.9717
Pretty Stable
Long Term Debt To Capitalization0.10.120.1314
Slightly volatile
Quick Ratio11.47.49119.7165
Slightly volatile
Net Income Per E B T0.80.880.957
Slightly volatile
Cash Ratio1.051.101418.3558
Slightly volatile
Days Of Inventory Outstanding139156170
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.00411.124
Slightly volatile
Fixed Asset Turnover0.580.660.7156
Slightly volatile
Debt Ratio0.130.12850.0347
Slightly volatile
Price Sales Ratio4.525.085.5411
Slightly volatile
Asset Turnover0.080.09250.1007
Slightly volatile
Gross Profit Margin0.780.870.9524
Slightly volatile

Pyxis Oncology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap86.6 M91.2 M351.8 M
Slightly volatile

Pyxis Fundamental Market Drivers

Cash And Short Term Investments126.9 M

Pyxis Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pyxis Oncology Financial Statements

Pyxis Oncology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Pyxis Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Pyxis Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pyxis Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue8.8 M4.4 M
Total Revenue16.1 M17 M
Cost Of Revenue475 K451.2 K
Stock Based Compensation To Revenue 0.72  0.64 
Sales General And Administrative To Revenue 1.42  1.26 
Research And Ddevelopement To Revenue 3.27  2.91 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.25  0.22 
Ebit Per Revenue(4.99)(5.24)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Pyxis Stock Analysis

When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY